Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT05156281
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Relapsing Multiple Sclerosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- Remibrutinib — DRUGtablet taken orally
- Teriflunomide — DRUGcapsule taken orally
Study Details
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Key Dates
- Start date
- Dec 13, 2021
- Status verified
- May 2026
- Primary completion
- Jul 23, 2026
- Completion
- Oct 30, 2030
Study Design
- Enrollment
- 1,007 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Remibrutinib - CoreRemibrutinib tablet and matching placebo of teriflunomide capsule
- Active Comparator: Teriflunomide - CoreTeriflunomide capsule and matching placebo remibrutinib tablet
- Experimental: Remibrutinib - ExtensionParticipants on remibrutinib in Core will continue on remibrutinib tablet
- Experimental: Remibrutinib - Extension (on teriflunomide in Core)Participants on teriflunomide in Core will switch to remibrutinib tablet
Primary Outcome Measure
Annualized relapse rate (ARR) of confirmed relapses [Core Part] [ Time Frame: From Baseline, up to 30 months ]
Locations (50)
Find similar trials in Phoenix, AZ
Related Studies
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)PHASE3 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Palo Alto, California
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPHASE3 · Recruiting · TG Therapeutics, Inc. · Birmingham, Alabama
- A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast MilkRecruiting · TG Therapeutics, Inc. · San Francisco, California
- A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)Recruiting · TG Therapeutics, Inc. · Birmingham, Alabama